• ISBN13:


  • ISBN10:


  • Format: Paperback
  • Copyright: 2008-02-28
  • Publisher: Ios Pr Inc

Note: Supplemental materials are not guaranteed with Rental or Used book purchases.

Purchase Benefits

  • Free Shipping On Orders Over $35!
    Your order must be $35 or more to qualify for free economy shipping. Bulk sales, PO's, Marketplace items, eBooks and apparel do not qualify for this offer.
  • Get Rewarded for Ordering Your Textbooks! Enroll Now
List Price: $140.00 Save up to $35.00
  • Rent Book $126.00
    Add to Cart Free Shipping


Supplemental Materials

What is included with this book?


Proper treatment and early diagnosis of primary immunodeficiencies is a worldwide public heath priority and therefore the tenth volume of Pharmaceuticals Policy and Law: Focus on Immunodeficiencies focuses on awareness about this issue for the sake of many patients in need. Primary immunodeficiencies in particular are a major public health issue and are still nowadays too often ignored. However, ignoring them is an extremely costly way to handle the issue. Not treating these patients can be an additional burden to the economy or just result in poverty and increased ill-health. Unfortunately, because symptoms of primary immunodeficiencies often manifest as common affections such as pneumonia, bronchitis, or gastroenteritis, without proper knowledge about what causes these symptoms, many doctors focus on treating the symptoms rather than the cause. This leads to a huge waste of healthcare resources as the infections keep coming back and costly and prolonged hospital stays are needed. Proper treatment through immunoglobulin replacement therapy has been shown to significantly reduce episodes of infection, hospital stays and enable affected people to lead normal active professional lives. In order to put an end to this tendency, this volume strives to facilitate the increase of awareness of the issue.

Table of Contents

Introduction and Definition
What are immunodeficiencies?
Living with primary immunodeficiency
Living life to the fullest
Treatment and Care
Treatment options for primary immunodeficiencies
Immunoglobulins: Unique therapies
The role of nurses in recognizing and caring for patients with primary immunodeficiencies
Immunodeficiencies in the EU
Primary immunodeficiencies in Europe
Primary immunodeficiencies in the EU: The physician's perspective
PIDs in the EU: A regulator's perspective of intravenous immunoglobulins (IVIGs)
Action for rare diseases in the European Union
Immunodeficiencies in the EU: Viewpoint from the European Parliament
Immunodeficiencies in the U.S.
Primary immunodeficiency diseases in the United States: The patient perspective
Population prevalence of diagnosed primary immunodeficiency diseases in the United States
Immunodeficiencies and the developing world
Primary immunodeficiencies in India: The patient perspective
Primary immunodeficiencies in Argentina: The patient perspective
Primary immunodeficiency disorders in India: The physician perspective
Impact of intravenous immunoglobulin (IVIG) treatment among patients with Primary Immunodeficiency diseases
The value of early diagnosis and treatment of patients with primary antibody deficiencies
Immunodeficiencies tomorrow
Primary Immunodeficiencies (PID): The importance of earliest possible diagnosis
Meeting the global demand for immunoglobulins
Core SPC for Human Normal Immunoglobulin for Intravenous Use, CPMP/ BPWG/869/rev 2 of 29 July 2004
Core SPC for Human Normal Immunoglobulin for Subcutaneous and Intramuscular Use, EMEA/CPMP/BPWG/282/00 of 25 July 2002
European Pharmacopoeia 5.3 01/2006:0338, Monograph Human Normal Immunoglobulin
Directive 89/381/EEC of June 1989
Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003
Directive 2004/33/EC of 22 March 2004
Author Index Volume 10 (2008)
Table of Contents provided by Blackwell. All Rights Reserved.

Rewards Program

Write a Review